Multi-academic Center Study of Xofigo Patients
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/27/2019 |
| Start Date: | December 3, 2018 |
| End Date: | April 15, 2019 |
A Retrospective, Longitudinal Multi-Center Study of Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer
The study will be conducted from a real-world perspective to describe treatment sequences
involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate
cancer (mCRPC) and assess overall survival (OS) associated with treatment sequences involving
radium-223 and chemotherapy. While clinical trials of radium-223 has demonstrated a survival
benefit in the treatment of mCRPC, both pre and post- docetaxel, study lacked exposure to
second generation androgens and hence could not assess outcomes pre or post abiraterone or
enzalutamide.
The specific objective of this study is to describe and compare the clinical outcomes between
treatment sequences for patients with mCRPC where 1) radium-223 is used (alone or in
combination with abiraterone or enzalutamide) prior to chemotherapy versus 2) radium-223 used
after chemotherapy in the treatment of mCRPC. The secondary objectives are to describe the
safety patterns of docetaxel use among mCRPC patients who received chemotherapy post
radium-223.
involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate
cancer (mCRPC) and assess overall survival (OS) associated with treatment sequences involving
radium-223 and chemotherapy. While clinical trials of radium-223 has demonstrated a survival
benefit in the treatment of mCRPC, both pre and post- docetaxel, study lacked exposure to
second generation androgens and hence could not assess outcomes pre or post abiraterone or
enzalutamide.
The specific objective of this study is to describe and compare the clinical outcomes between
treatment sequences for patients with mCRPC where 1) radium-223 is used (alone or in
combination with abiraterone or enzalutamide) prior to chemotherapy versus 2) radium-223 used
after chemotherapy in the treatment of mCRPC. The secondary objectives are to describe the
safety patterns of docetaxel use among mCRPC patients who received chemotherapy post
radium-223.
Inclusion Criteria:
- Received at least one dose of radium-223 after mCRPC diagnosis
- Received at least one prescription or dose of chemotherapy for treatment of mCRPC
Exclusion Criteria:
- No documented visceral metastasis at initiation of radium-223
We found this trial at
1
site
Click here to add this to my saved trials
